Scandion Oncology Dirección

Dirección controles de criterios 0/4

El CEO de Scandion Oncology's es Francois Martelet, nombrado en Jan 2023, tiene una permanencia de 1.25 años. posee directamente un 0.027% de las acciones de la empresa, con un valor de SEK16.21K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 2.6 años, respectivamente.

Información clave

Francois Martelet

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	2.7yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06

CEO

Francois Martelet (63 yo)

1.3yrs

Permanencia

Dr. Francois Regis Martelet, M.D. is a Non-executive Director of Novigenix SA since June 2019. He had been the Chief Executive Officer of Vivesto AB (formerly known as Oasmia Pharmaceutical AB (publ)) sinc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jan Stenvang	Chief Scientific Officer	1.3yrs	sin datos	3.32% DKK 1.8m
Francois Martelet	Chief Executive Officer	1.3yrs	sin datos	0.027% DKK 15.2k
Johnny Stilou	Chief Financial Officer	2.8yrs	sin datos	0.033% DKK 18.1k
Morten Nissen	General Counsel	no data	sin datos	sin datos
Mads Kronborg	Head of External Communication	2.3yrs	sin datos	sin datos
Lars Damstrup	Chief Medical Officer	1.3yrs	sin datos	sin datos

1.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de SCOL no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jorgen Vilhelm Bardenfleth	Independent Vice-Chairman of the Board	6.3yrs	sin datos	1.12% DKK 620.1k
Palle Christophersen	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Schilsky	Member of Clinical Advisory Board	3.1yrs	sin datos	sin datos
Alejandra Maria Cristina Mork	Independent Director	2.1yrs	sin datos	sin datos
Eric Cutsem	Member of Clinical Advisory Board	2.7yrs	sin datos	sin datos
Josep Tabernero	Member of Clinical Advisory Board	2.7yrs	sin datos	sin datos
Susan Bates	Member of Scientific Advisory Board	no data	sin datos	sin datos
Keld Jorgensen	Independent Director	2.1yrs	sin datos	sin datos
Thomas T. Seufferlein	Member of Clinical Advisory Board	2.7yrs	sin datos	sin datos
Martin Moller	Independent Chairman of the Board	3yrs	sin datos	0.015% DKK 8.5k
Martine van Vugt	Independent Director	2.1yrs	sin datos	sin datos

2.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de SCOL no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Scandion Oncology Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

High number of new and inexperienced directors

Scandion Oncology A/S Announces CEO Changes

Recent updates

New major risk - Financial position

Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial

New major risk - Revenue and earnings growth

Scandion Oncology A/S to Report Q3, 2024 Results on Nov 27, 2024

New major risk - Market cap size

Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial

Scandion Oncology A/S, Annual General Meeting, Apr 24, 2024

Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101

Price target decreased by 13% to kr2.80

Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial

Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data

Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer

Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023

The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101

Forecast to breakeven in 2024

Price target decreased by 31% to kr3.40

Forecast to breakeven in 2024

Price target increased by 27% to kr4.95

Scandion Oncology Receives Opinion from the European Patent Office on Composition of Matter Patent-Application for Lead Compound SCO-101

Scandion Oncology Appoints Jan Stenvang, Ph.D., Chief Scientific Officer and Member of Executive Management

Forecast to breakeven in 2024

Scandion Oncology Appoints Francois Martelet as New Chief Executive Officer, Effective from January 2, 2023

Scandion Oncology A/S to Report Fiscal Year 2022 Results on Mar 22, 2023

Consensus revenue estimates fall by 63%

Price target decreased to kr3.90

High number of new and inexperienced directors

Scandion Oncology Initiates Part 3 of CORIST Phase II Trial Studying Scandion’s Lead Compound SCO-101 as Combination Treatment in Patients with Metastatic Colorectal Cancer

Scandion Oncology Announce Topline Results from Part 2 of the Corist Phase II Trial

Scandion Oncology A/S Announces CEO Changes

Scandion Oncology Announces Change to Its Executive Management

Scandion Oncology A/S Receives Approvals for Next Parts of the Corist Trial

Scandion Oncology Extends PANTAX Trial Due to Better-Than-Expected Tolerability of SCO-101

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Consensus forecasts updated

Scandion Oncology Announces Resignation of Thomas Feldthus from the Board of Directors

Scandion Oncology A/S Announces Chief Medical Officer Change

Price target increased to kr26.00

High number of new and inexperienced directors

Scandion Oncology A/S Expands Clinical Development with Internationalization of the CORIST-Trial

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Scandion Oncology A/S Announces That Data from CORIST-Trial to Be Presented At ASCO Gastrointestinal Cancers Symposium

Scandion Oncology Receives Approval for Initiating the CORIST Part 2 Trial

Scandion Oncology Receives German Trial Approval for PANTAX Ib Study

Chief Financial Officer Carit Andersen has left the company

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Scandion Oncology A/S Reports Positive Interim Results from the Corist Phase II Study

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

Scandion Oncology Appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations

Scandion Oncology A/S Adjusts the Pantax Pancreatic Cancer Study

Scandion Oncology A/S Finalizes the First 12 Patients in CORIST Study

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

New 90-day low: kr22.20

New 90-day low: kr34.30

New 90-day low: kr35.00

Scandion Oncology A/S Announces Modified Timelines for Clinical Studies

Scandion Oncology A/S Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of A Clinical Trial in Patients with Pancreatic Cancer

Scandion Oncology Appoints Bo Rode Hansen as President, Effective October 1, 2020

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad